OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients
Celgene Invests in OncoMed's Demcizumab and up to Five Additional Preclinical Biologics Programs; OncoMed Leads Early Clinical Trials and Retains Co-Development, Co-Commercialization and Profit-Sharing Rights
OncoMed to Receive $177.25 Million Upfront, Including a $22.25 Million Equity Investment
OncoMed Pharmaceuticals, Inc. (OMED) and Celgene Corporation (CELG) today announced an agreement to jointly develop and commercialize up to six anti-cancer stem cell (CSC) product candidates from OncoMed's biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4).
Passport Energy Ltd. Announces Additional Land Acquisition Details
Passport Energy Ltd. (PPO - TSX Venture, PPOZF - OTC),("Passport") provides, further to its news release dated November 27, 2013, the following additional details of the previously announced land acquisition.
Passport has entered into an agreement with a private oil and gas company to acquire 22 1/4 contiguous sections (5,760 acres) of 100% owned land in the Hardy area of SE Saskatchewan for $600,000 cash. The acquisition will be subject to certain conditions including Passport completing due diligence on the properties, obtaining a satisfactory title opinion on the properties, completing a financing, and completing the formal agreement between Passport and the vendor.
Passport Energy Ltd. Announces Land Acquisition
Passport Energy Ltd. (PPO - TSX Venture), ("Passport") advises that it has entered into an agreement with a private oil and gas company to acquire 22 1/4 contiguous sections (5,760 acres) of 100% owned land in the Hardy area of SE Saskatchewan. The acquisition price will, subject to certain conditions being met, be paid by Passport in cash. Passport believes the acreage is located in a more prospective area of the new light oil Bakken play trend that it has been exploring for the past 2 years.
Passport Energy Ltd. Announces 51-101 Reserve Report and Production Update
Passport Energy Ltd. (PPO - TSX Venture), ("Passport" or the "Company") is pleased to announce that it has filed its 51-101 reserve report on its reserves in the Hardy area of SE Saskatchewan.
Corporate Reserve Update
GLJ has assigned Passport, total proved company interest reserves of 49,000 bbls (166,000 gross bbls), representing an 81% increase in the company's total proved reserves when compared to last year's evaluation.
ARIAD Announces Positive Opinion by the European Medicines Agency on the Continued Availability of Iclusig in Patients with Leukaemias
Recommendations made to minimize risk of occlusive vascular events
ARIAD Pharmaceuticals, Inc. (ARIA) today announced adoption of a positive opinion by the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) on the continued availability of Iclusig® (ponatinib) in the EU for use in patients in its authorized indications. Following its review of updated clinical-trial data on Iclusig, the CHMP made a series of recommendations on measures to help minimize the risk of occlusive vascular events in patients taking Iclusig. The authorized indications of Iclusig, as approved in July 2013, are as follows:
Inovio Pharmaceutical's DNA Vaccine for the Deadly MERS Virus Induces Robust Immune Response in Preclinical Trial
No vaccine exists for the MERS virus that has killed 42% of those infected
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, demonstrating the potential for a SynCon® DNA vaccine to prevent and treat this deadly virus.
Since 2012, when the virus was first identified, 153 cases from nine Middle Eastern countries have been reported and, alarmingly, 42% of these cases have been fatal.
NovaBay Pharmaceuticals Announces Publication of Novel Surgical Procedure for Life Threatening Wounds and Flesh Eating Bacteria
New Procedure Utilizes Adjunctive NeutroPhase® Therapy Paper in the Medical Journal WOUNDS Describes First Successful Procedure that Removes Toxins from Wounds with Less Invasive Debridement and Avoids Possible Amputation
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced the publication of a scientific paper by Dr. John R. Crew of Seton Medical Center, Daly City, California, describing the first use of adjunctive NeutroPhase®* irrigation therapy in conjunction with Negative Pressure Wound Therapy (NPWT) to successfully manage the severely-infected wound in the arm of a patient with life-threatening ‘flesh-eating’ disease.
Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO(R) and Provides 2014 Guidance
Horizon to Host Conference Call / Webcast Today at 8:00 a.m. EST
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that it has entered into an agreement to acquire from AstraZeneca AB the U.S. rights to VIMOVO® (naproxen/esomeprazole magnesium) delayed-release tablets, further expanding Horizon's focus on key primary care physician targets in the U.S. VIMOVO is approved in the U.S. to relieve the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of stomach (gastric) ulcers in patients at risk of developing stomach ulcers from treatment with NSAIDs. AstraZeneca will retain ex-U.S. rights to VIMOVO.
Spherix Announces Settlement Agreement and Continued Monetization of Patent Portfolio
Spherix Incorporated (SPEX) -- an intellectual property development company committed to the fostering and monetization of intellectual property, announced today that its wholly owned subsidiary, CompuFill LLC, has entered into a settlement and license agreement with a leading technology company.
This is the first settlement and license agreement for the CompuFill portfolio since Spherix acquired North South Holdings Inc. in September of 2013. Ongoing infringement enforcement continues as Spherix's model of patent monetization grows in both scope and size.
The CompuFill patents, each in the "on-line pharmacy automated refill system" sector, trace priority back to October 1997.
Intellipharmaceutics / Par to Make Immediate Commercial Launch of 15 and 30 mg Generic Focalin XR(R)
-- FDA Issues Final Approval of 15 mg, With 180 Days of Exclusivity, and 30 mg; and -- Tentative Approvals for the Company's 5, 10, 20 and 40 mg Strengths
Intellipharmaceutics International Inc. (IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company") a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs today announced that the U.S. Food and Drug Administration ("FDA") has granted final approval of the Company's dexmethylphenidate hydrochloride extended-release capsules for the 15 and 30 mg strengths. Commercial sale of these strengths will be launched immediately by the Company's commercialization partner in the United States Par Pharmaceutical, Inc. ("Par").
Discovery of a Conventional Natural Gas Reservoir in the Lower St. Lawrence Area
Petrolympic Ltd. ("Petrolympic" or the "Company") (TSX VENTURE:PCQ) is pleased to announce the discovery of a conventional reservoir of natural gas on its joint venture property in the Lower St. Lawrence area (the "Property") located in the Appalachian Basin of Quebec, which was announced by the Operator, Ressources & Energie Squatex Inc., ("Squatex") in its press release dated November 15, 2013 (see www.sedar.com). The Company holds an interest in 217,370 hectares (536,941 acres) of the Property through a joint venture with Squatex.
Catalyst Pharmaceutical Partners Announces Publication of Preclinical Proof-of-Principle of CPP-115 Efficacy in Suppressing Infantile Spasms in Epilepsia
Phase I Multiple-Ascending Dose Study to Be Initiated in 2014
Catalyst Pharmaceutical Partners, Inc. (CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, today announced that the journal Epilepsia has accepted for publication an original research paper that demonstrates proof of concept of CPP-115 suppressing infantile spasms (IS) in a pre-clinical study. CPP-115 is Catalyst's next-generation GABA aminotransferase inhibitor being developed for the treatment of IS. Catalyst also announced plans to initiate a Phase I multiple-dose ascending study in the first half of 2014 to evaluate the safety and tolerability of multiple ascending oral doses of CPP-115.
Cadence Pharmaceuticals Reports Positive Outcome In OFIRMEV® Patent Litigation
Cadence Pharmaceuticals, Inc. (CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the U.S. District Court for the District of Delaware has ruled in favor of Cadence in the company's patent infringement lawsuit against Exela Pharma Sciences, LLC.
"We are very pleased with the Court's decision, as it confirms our belief in the strength and validity of the patents covering OFIRMEV," said Ted Schroeder, president and chief executive officer of Cadence. "Our focus remains on continuing to drive OFIRMEV's strong performance. We continue to gain market share and posted year-over-year sales growth of more than 100% in each quarter of 2013. We remain confident in our franchise, and look forward to updating investors further on our progress."
CollabRx Teams With Quest Diagnostics in Clinical Genetic Sequencing
CollabRx, Inc. (CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, today announced a multi-year, non-exclusive agreement with Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, related to medical annotation for new next-generation sequencing test services for cancer.
Under the agreement, Quest Diagnostics has the right to incorporate into clinical test reports for its next-generation sequencing cancer tests medical content, such as scientific literature, medical guidelines and published therapeutic protocols.
NW Bio's DCVax Featured On Fox News And Fox Business News
NYU's Dr. Marc Siegel Discusses DCVax And Its Life-Extending Potential As A Cancer Therapy
Northwest Biotherapeutics (NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that their vaccine was featured yesterday in news coverage on both Fox News and Fox Business News.
The segment was hosted for Fox by Dr. Marc Siegel, a Clinical Associate Professor at NYU's Langone Medical Center, who describes Northwest Biotherapeutics's DCVax as a potential life-extending treatment for all solid tumor cancers by using biomarkers from the patient's own tumor cells to activate the patient's immune system to fight the cancer in the patient's body.
Up to 8,120 g/t Gold Returned in Grab Samples Taken at King’s Bay Gold Corporation’s Menary Gold Project Located in the Rainy River Gold Camp of Northwest Ontario
King's Bay Gold Corporation (TSX.V:KBG.V ) is pleased to report that it has received the results of a sampling and assaying program undertaken at the Menary Gold Project.
As a result of this program, the company is now moving forward with its application to the Ontario Ministry of Northern Development & Mines for a permit to take a high-grade gold bulk sample of up to 999 tonnes to commence sometime during the winter or early spring of 2014.
Talisman Energy Announces $1.5 Billion All Cash Sale for Portion of Montney Position
Talisman Energy Inc. (Talisman) (TLM.TO)(TLM) announced that it has reached an agreement to sell part of its Montney acreage in northeast British Columbia to Progress Energy Canada Ltd. for a total cash consideration of CDN$1.5 billion.75% (~127,000 net acres) of Talisman's Montney position in the Farrell Creek and Cypress areas of British Columbia. 65 mmcfe/d of Farrell Creek production as of Oct 1, 2013, which is expected to increase in the fourth quarter as we conclude the 2013 completion program, and associated facilities. CDN$800 million of remaining third party capital carry estimated at 2013 year end (~CDN$870 million at effective date October 1, 2013).
Arena Pharmaceuticals and Eisai Expand Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) to Include Most Countries Worldwide
-- Collaboration to Focus on Global Commercialization and Development for Weight Management and Potential New Indications --
Arena Pharmaceuticals, Inc. (ARNA) and Eisai Inc. announced today the expansion of the BELVIQ® (lorcaserin HCl) marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. along with its parent company Eisai Co., Ltd. The expanded agreement provides Eisai with exclusive commercialization rights for all countries worldwide, except for South Korea, Taiwan, Australia, Israel and New Zealand. This agreement amends and restates the previous agreement that granted Eisai rights to commercialize BELVIQ in most of North and South America. Eisai's commercialization rights are subject to applicable regulatory approval.
Advanced Proteome Therapeutics Corporation Advances Anti-Cancer Program
Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE:APC) is pleased to announce the achievement of an important milestone in its anti-cancer program with its collaborators by demonstrating that the first of a series of the Company's site-specifically labeled protein conjugates binds tightly to specific tumor cells and concentrates in tumor tissue, when administered intravenously, in animals. We have also demonstrated that the protein itself retards the growth of established tumors in animals. These results provide a basis for augmenting the protein's fundamental anti-cancer activity with additional entities, such as chemotherapeutics and/or other targeting entities. In addition, initial studies indicate that the Company has discovered a novel method for substantially increasing the affinity of the protein toward such cancer cells, with potential for yielding superior, first in its class, anti-cancer therapeutics.
ARC Resources Ltd. announces a $915 million capital program targeting 17 per cent growth in production in 2014
ARC Resources Ltd. ("ARC") announced today that its Board of Directors has approved a $915 million capital program for 2014 directed at high value oil and liquids-rich gas plays and investment in its low cost Montney gas assets. ARC expects annual average production growth of approximately 17 per cent in 2014.
Myron Stadnyk, ARC's President and Chief Executive Officer, said, "With a clear line of sight toward future value creation, we are building a long-term sustainable business on the back of our world class assets while continuing to pay a meaningful dividend to our shareholders.